Managing Age-Related Clinical Issues in Hemophilia

Slides:



Advertisements
Similar presentations
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
Advertisements

Ian Graham et al. European Heart Journal 2007;28:
The United States & Heart Disease Presented today by; Matt Lorup, Keith Arline, & Nick Knight.
Public Health. CVDDiabetesCancer Antibiotic Resistance.
Northern England Strategic Clinical Network Conference 15 th May 2015.
EPIDEMIOLOGY The study of the distribution and determinants of health related states and events in specified population and application of this.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Physical Activity and Health
Preventing Cardiovascular Disease
Copyright © 2007 American Medical Association. All rights reserved.
Κολπικη μαρμαρυγη σε ασθενεις με αποφρακτικη υπνικη απνοια
Familial Chylomicronemia Syndrome
The Future of Osteoporosis: Improving Care Along the Way
Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.
Prevention Cardiovascular disease
HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.
Chronic Hepatitis C Virus Infection
RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL
Recognizing Your Risk for Cardiovascular Disease
Managing Women Living With HIV Infection
Starting Strong: Initial Evaluation of the Patient With HCV
An Endocrinology Clinic in Dyslipidemia
HCV: Who Should We Screen and Why?
Cardiovascular Disease (CVD) in Texas
Overview of Disparities
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Individualizing Prophylaxis in Hemophilia
Best Practices in Screening and Linkage to Care in Hepatitis C Virus
Resistant Hypertension
Bone Biology and Osteoporosis: Back to the Basics
SGLT2 Inhibitors in the Modern Era: Why and Where?
Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.
HCV Screening.
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
HBV Infection: Some Sobering Facts
CVD Secondary Prevention plans within Thames Valley
HBV Care Models: Community Collaborations for Best Practices
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Precision Management of RA and Comorbidities
Cardiovascular Comorbidities A Common Occurrence With COPD
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Evaluating Next-Generation BTK Inhibitors
Virological tools to diagnose and monitor hepatitis C virus infection
Issues in the Management of Hemophilia: A Best Practice Series
Aspirin in Cardioprevention:
Bone Biology and Osteoporosis: Back to the Basics
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Program Goals Overview Is NEDA a Reasonable Target?
Hepatitis C: After the Diagnosis
Current Challenges in Managing Hemophilia
Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection  Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.
Optimizing Joint Health in Hemophilia
Bone Biology and Osteoporosis: Back to the Basics
What is cardiovascular disease?
Healthy With HIV.
Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators
Clinical Challenges and Updates in Managing Seizure Clusters
Program Goals Overview Is NEDA a Reasonable Target?
Selecting Treatment Approaches in Hemophilia
CVD Secondary Prevention plans within Thames Valley
Addressing Cardiovascular Events:
Prevalence and costs of treating uncomplicated stage 1 hypertension in primary care: a cross-sectional analysis by James P Sheppard, Kate Fletcher, Richard.
Volume 72, Issue 3, Pages (August 2007)
Minimal Residual Disease and Hematologic Malignancies
Exploring the Use of Adeno-Associated Virus for Gene Therapy
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Presentation transcript:

Managing Age-Related Clinical Issues in Hemophilia

Program Goals

Introduction

Hypertension

Prevalence of Hypertension

Explaining the High Prevalence of Hypertension

Management of High Blood Pressure

Importance of Treatment

Challenges to Management

Cardiovascular Disease

Risk Factors for CVD in Patients With Hemophilia

Approaching Factor Replacement in Patients With CVD

Management of Acute Coronary Events

Management of Atrial Fibrillation

Obesity

Defining Obesity

Prevalence of Obesity in the United States

Consequences of Obesity

Strategies for Addressing Obesity

Bone Health

Osteoporosis and Hemophilia

Risk of Fractures

Potential Mechanism of Action

Management of Osteoporosis

Hepatitis C Virus

Hepatitis C Virus in Patients With Hemophilia

HCV Infection Affects Patients With Hemophilia More Severely

Management of Patients With HCV

Treatment of HCV

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)